Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.66 |
| ▸ | RAB9A | P51151 | 10/20 | 0.66 |
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17266541 | 1.00 | NPC1 (0.66) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL21275831 | 0.84 | JAK2 (0.59) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL9089971 | 0.83 | RAB9A (0.63) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL11794850 | 0.82 | NPC1 (0.58) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL222110 | 0.82 | NPC1 (0.58) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL29695306 | 0.82 | NPC1 (0.58) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL29655094 | 0.82 | NPC1 (0.60) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL6179239 | 0.82 | NPC1 (0.60) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL31288927 | 0.82 | NPC1 (0.66) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL29018750 | 0.81 | RAB9A (0.61) | NPC1RAB9APKMGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936486-B | Heterocyclic compounds comprising pyridine as modulators of IL-12, IL-23 and/or IFN alpha responses | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | claimed |
| US-20240376128-A1 | N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-111032046-B | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2022213980-A1 | TYK2 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2022-10-13 | — | — | WO | disclosed |
| CN-109843874-B | Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer | 加利福尼亚大学董事会 | 2022-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376128-A1 | N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | CYP4A11, CYP4B1, DHPS | NPC1 364/4885RAB9A 863/4885PKM 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.